Prognostic factors related with survival in patients with pancreatic adenocarcinoma

Table 4 Molecular and novel biomarkers as prognostic factors in pancreatic cancer

References	No. of patients	Results
Molecular markers
Neoptolemos et al[64]	48	mOS, 26.2 mo for patients with high hENT1 expression vs 17.1 for those with low hENT1 expression who treated with gemcitabine (P = 0.002)
Sinn et al[68]	160	Strong stromal SPARC expression was associated with worse DFS and OS (strong vs not-strong DFS 9.0 vs 12.6 mo, P = 0.005; OS 19.8 vs 26.6 mo (P = 0.033).Cytoplasmic SPARC expression was also associated with worse patient outcome (positive vs negative DFS 7.4 vs 12.1 mo, P = 0.041; OS 14.1 vs 25.6 mo, P = 0.011) in patients with pancreatic cancer who received gemcitabine as adjuvant CT
Blackford et al[76]	114	mOS,14.2 mo in patients without SMAD4 gene inactivation vs 11.5 mo for those with inactivation (P = 0.006)
Oshima et al[77]	106	Loss of SMAD4 expression was significantly associated with shorter OS and it was found to be an independent prognostic factor for both OS and DFS
Novel biomarkers
Xue et al[86]	106	mOS for patients with a higher NEDD9 expression was significantly shorter than that of patients with lower NEDD9 expression. NEDD9 was an independent factor of poor prognosis
Xia et al[88]	80	A higher FoxM1 expression had a significantly shorter survival time compared to patients with lower FoxM1 expression and FoxM1 was found to be an independent factor for survival

mOS: Median overall survival; DFS: Disease-free survival; hENT1: Human equilibrative nucleoside transporter 1; SPARC: Secreted protein and rich in cysteine; CT: Chemotherapy; FOXM1: Forkhead box M1.